Ich kaufe jetzt: Motif Bio PLC - 500 Beiträge pro Seite
eröffnet am 13.12.16 17:17:57 von
neuester Beitrag 14.02.19 21:53:39 von
neuester Beitrag 14.02.19 21:53:39 von
Beiträge: 10
ID: 1.242.947
ID: 1.242.947
Aufrufe heute: 0
Gesamt: 1.350
Gesamt: 1.350
Aktive User: 0
ISIN: GB00BVVT4H71 · WKN: A14Q8Q
0,0016
EUR
-20,00 %
-0,0004 EUR
Letzter Kurs 11.02.20 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,7400 | +44,50 | |
| 4,7450 | +35,57 | |
| 11,020 | +32,77 | |
| 25,09 | +30,34 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,4000 | -11,69 | |
| 8,0100 | -12,85 | |
| 2,2850 | -15,68 | |
| 0,9300 | -17,70 | |
| 1,6052 | -30,21 |
Feedback
Thilo Rohrhirsch, Geschäftsführer von Acevo, traut der Aktie von Motif Bio viel zu, da neue Antibiotika gegen multiresistente Bakterien dringend benötigt werden.
http://www.finanzen.net/nachricht/aktien/Euro-am-Sonntag-Tip…
http://www.finanzen.net/nachricht/aktien/Euro-am-Sonntag-Tip…
seit langem auf meiner WL 
(neben auch der britischen OptiBiotix Health Plc)
(neben auch der britischen OptiBiotix Health Plc)
Motif Bio worth 114p!!!
Motif Bio worth 114p, says growth company specialist 
http://www.proactiveinvestors.co.uk/companies/news/169268/mo…
Motif Bio Plc (LON:MTFB) – BUY*: Update note
Market Cap: £41m; Current Price: 23p; Target Price: 90p (from 140p)
http://www.proactiveinvestors.co.uk/columns/northland-capita…
Market Cap: £41m; Current Price: 23p; Target Price: 90p (from 140p)
http://www.proactiveinvestors.co.uk/columns/northland-capita…
Trading Spotlight
Das sind sehr gute News:
Motif Bio announces iclaprim granted Orphan Drug Designation by US FDA for treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis
NEW YORK, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (Nasdaq:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the US Food and Drug Administration (“FDA”) has granted its investigational drug candidate, iclaprim, Orphan Drug Designation for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis.
Orphan designation grants special status to a drug or biologic under development to treat a rare disease or condition and qualifies the sponsor of the product for various development incentives, including tax credits for qualified clinical testing, waiver of user fees and potentially up to seven years of market exclusivity for the given indication, if approved.
“Staphylococcus aureus, including MRSA, is one of the common causes of lung infections in patients with cystic fibrosis and we do not believe that any antibiotic has been approved for this indication. Some 80% or more of patients with cystic fibrosis die as a result of respiratory infections caused by a variety of bacteria, and MRSA infections have been growing in recent years,” said Graham Lumsden, Chief Executive Officer of Motif Bio. “Formulation development work is underway at Motif Bio to explore potential intravenous and inhaled formulations designed specifically for cystic fibrosis patients.”
Iclaprim has been studied in an animal model of chronic pulmonary methicillin resistant Staphylococcus aureus (“MRSA”) infection, which mimics the pathophysiology observed in the lungs of patients with cystic fibrosis. These data will be presented at IDWeek on October 6, 2017 in San Diego, CA.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive Officer)
Robert Dickey IV (Chief Financial Officer)
Investor Resources
Motif Bio announces iclaprim granted Orphan Drug Designation by US FDA for treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis
NEW YORK, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (Nasdaq:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the US Food and Drug Administration (“FDA”) has granted its investigational drug candidate, iclaprim, Orphan Drug Designation for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis.
Orphan designation grants special status to a drug or biologic under development to treat a rare disease or condition and qualifies the sponsor of the product for various development incentives, including tax credits for qualified clinical testing, waiver of user fees and potentially up to seven years of market exclusivity for the given indication, if approved.
“Staphylococcus aureus, including MRSA, is one of the common causes of lung infections in patients with cystic fibrosis and we do not believe that any antibiotic has been approved for this indication. Some 80% or more of patients with cystic fibrosis die as a result of respiratory infections caused by a variety of bacteria, and MRSA infections have been growing in recent years,” said Graham Lumsden, Chief Executive Officer of Motif Bio. “Formulation development work is underway at Motif Bio to explore potential intravenous and inhaled formulations designed specifically for cystic fibrosis patients.”
Iclaprim has been studied in an animal model of chronic pulmonary methicillin resistant Staphylococcus aureus (“MRSA”) infection, which mimics the pathophysiology observed in the lungs of patients with cystic fibrosis. These data will be presented at IDWeek on October 6, 2017 in San Diego, CA.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive Officer)
Robert Dickey IV (Chief Financial Officer)
Investor Resources
Ich finde diesen Wert sehr interessant. Die Motif Bio entwickelt sehr erfolgreichAntibiotika gegen multiresistente Keime. Hierbei ist besonders das Iclaprim hervorzuheben. Dieses Antibiotikum wirkt auch gegen den sog. MSRA Keim .Die Wirksamkeit und Sicherheit wird aktuell in einer Phase III Revive Studie an weltweit 1200 Patienten gegenüber der Standarttherapie eingesetzt. Iclaprim hat eine andere Wirkungsweise der sich signifikant von den sechs übrigen Antibiotika unterscheidet. Mitt2 2017 gab es schon sehr positive Ergebnisse in dieser Phase III Studie. Sollten diese sich bestätigen, könnte die Zulassung im Jahr 2018 bevorstehen.
Die Marketcap ist mit ca 100 Mio € noch sehr überschaubar.
Die Marketcap ist mit ca 100 Mio € noch sehr überschaubar.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,10 | |
| +18,18 | |
| -5,46 | |
| -1,45 | |
| +0,93 | |
| +0,01 | |
| -7,21 | |
| +1,08 | |
| +0,93 | |
| +6,78 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 224 | ||
| 124 | ||
| 105 | ||
| 64 | ||
| 55 | ||
| 39 | ||
| 38 | ||
| 35 | ||
| 27 | ||
| 26 |
